ABEER FAYYAD: Open Payments
NPI 1093704785 · FLINT, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$797 in 40 payments from 12 companies in 2025. Trend: 2023 $658 · 2024 $441 · 2025 $797
Food & beverage: $797
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $171 |
| Corcept Therapeutics | 3 | $150 |
| Edwards Lifesciences Corporation | 1 | $117 |
| PFIZER INC. | 5 | $97 |
| AstraZeneca Pharmaceuticals LP | 4 | $63 |
| Amgen Inc. | 3 | $48 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $40 |
| Novo Nordisk Inc | 2 | $38 |
| GlaxoSmithKline, LLC. | 1 | $24 |
| Lilly USA, LLC | 1 | $16 |
Products named: Korlym, VRAYLAR, SAPIEN 3 Ultra RESILIA, ELIQUIS, BREZTRI, OTEZLA, XIFAXAN, QULIPTA.
Industry payments across MI — which companies pay providers there.
